Capital allocation

H.U. Group’s testing and related services measure specimens entrusted by medical institutions and report the results. Operating profit was ¥31m in the year ended March 2026. The company cites growth in genetic and specialized testing, price adjustments and improved testing operations. Segment depreciation was ¥13.598bn, showing the costs behind keeping equipment and people at work. Consolidated operating profit of ¥4.780bn covers a different scope, including diagnostic reagents, other businesses and corporate-cost adjustments.

Kurita combines equipment handover followed by maintenance and chemicals with water supply using equipment it owns. The latter involves construction, investment and operation, while contract-termination settlement gains are recorded separately from revenue. Recurring contract-based services’ 17% revenue share and the broader service-business ratio of 72.1% measure different things. Asset ownership and operating responsibilities reveal how customer relationships continue.

ORIX expanded from leasing equipment to businesses into operations and investment. FY2026 capital gains of ¥265.2bn measure profit; Cash In of ¥1.1tn and Cash Out of ¥800bn measure capital recoupment and new investment. Greenko’s ¥95.0bn includes sale and valuation gains. Decisions about what to own, where to take part in operations and when to recover capital connect the group’s varied businesses.